| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03217591 | A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria | PHASE2 | COMPLETED | 156 | — | — | Aug 1, 2017 | Aug 20, 2019 | Sep 15, 2022 | 54 | United States |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. Causality relationship to study drug was per Investigator assessment.
Urine samples were collected for the analysis of UACR. UACR (milligrams per gram \[mg/g\]) was calculated as urine albumin (mg per deciliter \[mg/dL\]) / urine creatinine (g/dL). Change from Baseline was calculated as the average of the UCAR values at Weeks 8 and 12 minus the Baseline value. Data were analyzed using a mixed-effects model repeated measures (MMRM) analysis with change from Baseline in log-transformed UACR as the response variable, treatment, visit, treatment-by visit interaction, and Baseline estimated glomerular filtration rate stratum as fixed effects, Baseline log-transformed UACR and Baseline mean arterial pressure as covariates, and unstructured as the variance-covariance structure.
| Arm | Type | Description |
|---|---|---|
| IW-1973 Low Dose | EXPERIMENTAL | Administered daily for 12 weeks |
| IW-1973 High Dose | EXPERIMENTAL | Administered daily for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo to match experimental drug administered daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| IW-1973 | DRUG | Oral Tablet |
| Placebo | DRUG | Oral Tablet |
Key Inclusion Criteria: * Patient is an ambulatory male or female from 25 to 75 years old at the Screening Visit. * Patient has type 2 diabetes diagnosed by a physician or nurse practitioner ≥6 months before the Screening Visit, has been on ≥1 antihyperglycemic medication for ≥12 weeks preceding th...